ArticleBrain pathology (Zurich, Switzerland)2026
Brain calcification-associated JAM2 pathogenic mutations impair JAM2-JAM3 tight junction structure and the blood-brain barrier integrity.
Article in Brain pathology (Zurich, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brain calcification-associated JAM2 pathogenic mutations impair JAM2-JAM3 tight junction structure and the blood-brain barrier integrity.Brain pathology (Zurich, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Primary brain calcification (PBC) is a neurodegenerative disorder characterized by bilateral brain calcification. JAM2 is a PBC causative gene, encoding the tight junction protein JAM2 and critical for blood-brain barrier (BBB) integrity, with an uncertain pathogenic mechanism. We analyzed two JAM2 missense mutations identified in PBC patients using plasmid constructs, immunoprecipitation, flow cytometry, and structural modeling. A Jam2 knockout (KO) mouse model was generated to assess behavioral deficits, brain calcification, and BBB integrity via histology, Evans blue assay, and in situ hybridization. JAM2-W108C mutants showed abnormal localization, while JAM2-R108H specifically disrupted JAM2-JAM3 interaction, mirroring the pathogenic JAM3-E116K mutation. Jam2 KO mice exhibited midbrain calcification (von Kossa staining) and motor impairments (rotarod/beam-walking tests) at 6-12 months. JAM2 and JAM3 co-localized in brain endothelial cells, and KO mice demonstrated BBB leakage (Evans blue extravasation). The main pathogenic mechanism of JAM2-PBC should be associated with the impaired JAM2-JAM3 heterodimer formation, compromising tight junctions and BBB integrity. Our study indicates JAM2-JAM3 interaction as a potential therapeutic target for PBC and related brain calcification disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.